News

Leqvio (inclisiran) is the first small interfering RNA therapy approved to lower LDL cholesterol in certain adults at risk for life-threatening cardiovascular events.

But Paxlovid and molnupiravir will be available only at certain Walmart and Sam’s Club locations.

U.S. healthcare is the most expensive healthcare in the world. Many of the policies and programs designed to rein in those costs have been predicated on the idea that information about quality and price would make Americans more discerning shoppers of healthcare — and with that shopping would come some market discipline.

The country is becoming more diverse. Health plans need to adapt by making their provider networks as diverse as possible and committing to diversity in their management ranks.

CMS has started to experiment with a value-based version of Medicare Advantage that allows plans to tweak their offerings in various ways to see whether they might improve outcomes.

Insurers can assist with navigating the complexities of the healthcare system so caregivers can focus on what matters most — spending quality time with a loved one.

A review of real-world data from Israel didn't show any increase risk of myocardities or pericarditis.

'Just do it' is the takeaway from a review of 19 studies that found no difference between bouts of high-intensity physical activity and more moderate forms of aerobic exercise when it comes reducing liver fat.

A study conducted in China shows an association between metabolic-associated fatty liver disease and air pollution.

The FDA has approved Amgen and AstraZeneca’s Tezspire (tezepelumab-akko) for severe asthma. But the drug may have limited uptake in the near term, according to one analyst.

Readers were interested in what pharmacy benefit managers are doing and content that came out of the ISPOR annual meeting in 2021.

In 2021, readers were interested in the first mRNA vaccine trial for HIV, an increase in funding for an initiative to end HIV, and more.

News about counterfeit versions of Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) and Descovy (emtricitabine, tenofovir alafemamide) and the pause in the REMS program for clozapine were among the best read articles of 2021.

The most-read oncology news of 2021 included the FDA’s review of accelerated approvals, COVID-19 vaccine effectiveness in patients with blood cancer, and more.

Our best read stories about formularies include news about 2022 formularies from CVS Caremark and Express Scripts.

Interviews with key opinion leaders on a variety topics, such as work/life balance tips, race and equity, and the connection between pharmacy and telemedicine, topped the list of most-consumed multimedia in 2021.

News about interchangeable Semglee (insulin glargine-yfgn) was among the most read in 2021.

Although the pandemic remained a popular healthcare news story in 2021, there were other articles that captured readers’ attention, such as a perspective on the U.S. healthcare system, regulatory changes, and FDA updates.

Apotex's importation of Chantix (varenicline) and Express Scripts' formulary exclusions were among the best read articles this year that didn't concern COVID-19.

ICER's assessment of Biogen's controversial Alzheimer's drug, Aduhelm, was among the most read MHE articles about healthcare costs in 2021.

The FDA's warning about Xeljanz (tofacitinib) and other JAK inhiitors and the extension of its review of Janssen's CAR T therapy for multiple myeloma were among the best read articles about the agency in 2021.

COVID-19 remained the top healthcare story in 2021 with Managed Healthcare Executive® readers interested in vaccine news, how the pandemic has impacted care delivery and more.

The attention-getting articles about COVID-19 included news about Pfizer's booster and the FDA's rejection Zyesami (aviptadil) for treatment of COVID-19-related respiratory failure.

Many of the most-read articles from the print issues of Managed Healthcare Executive® focused on the cost of therapies.

The approval of the generic version of smoking-cessation drug Chantix (varenicline) garnered a lot of attention as did the OKs of Besremi (ropeginterferon alfa-2b-njft), a treatment for polycythemia vera, and Trudhesa (dihydroergotamine mesylate), a nasal spray for acute treatment of migraines.

Reporting of PRO in oncology clinical trials increased after standards from ISOQOL and others were published in 2013.

Patients with a variety of cancers spent much more money out of their own pocket than those in traditional plans. Some may be delaying treatment due to higher costs.